BACKGROUND: Breast cancer during pregnancy (BCP) is relatively rare and is associated with controversies about its biology and prognosis. Hence, we designed a case-control study to examine tumor features and outcome in a series of BCP patients diagnosed and treated in a single institution. MATERIAL AND METHODS: We identified 65 patients diagnosed with BCP and for each; we selected two non-pregnant breast cancer patients, who were matched for age, year of surgery, stage, and neoadjuvant chemotherapy. We then compared the differences in pathology, immunohistochemical features (ER, PR, HER2 and ki-67), disease-free (DFS) and overall survival (OS). RESULTS: We did not find any significant differences in tumor characteristics between the two groups. However, at a median follow-up of four years, BCP patients had an inferior DFS (HR 2.3; 95% CI 1.3-4.2), after adjustment for possible confounding covariates. No difference in OS was observed. However, upon restricting the analysis to patients who did not receive neoadjuvant chemotherapy, patients with BCP had inferior OS as well (HR 2.6; 95% CI 1.0-6.5). No association between induction of abortion and prognosis was observed. CONCLUSIONS: While we did not observe any differences in tumor features, BCP patients have poorer prognosis compared to age and stage-matched control. Further studies should try to elucidate reasons for such poor outcome.
BACKGROUND:Breast cancer during pregnancy (BCP) is relatively rare and is associated with controversies about its biology and prognosis. Hence, we designed a case-control study to examine tumor features and outcome in a series of BCPpatients diagnosed and treated in a single institution. MATERIAL AND METHODS: We identified 65 patients diagnosed with BCP and for each; we selected two non-pregnant breast cancerpatients, who were matched for age, year of surgery, stage, and neoadjuvant chemotherapy. We then compared the differences in pathology, immunohistochemical features (ER, PR, HER2 and ki-67), disease-free (DFS) and overall survival (OS). RESULTS: We did not find any significant differences in tumor characteristics between the two groups. However, at a median follow-up of four years, BCPpatients had an inferior DFS (HR 2.3; 95% CI 1.3-4.2), after adjustment for possible confounding covariates. No difference in OS was observed. However, upon restricting the analysis to patients who did not receive neoadjuvant chemotherapy, patients with BCP had inferior OS as well (HR 2.6; 95% CI 1.0-6.5). No association between induction of abortion and prognosis was observed. CONCLUSIONS: While we did not observe any differences in tumor features, BCPpatients have poorer prognosis compared to age and stage-matched control. Further studies should try to elucidate reasons for such poor outcome.
Authors: Sanah N Vohra; Andrea Walens; Alina M Hamilton; Mark E Sherman; Pepper Schedin; Hazel B Nichols; Katherine E Reeder-Hayes; Andrew F Olshan; Michael I Love; Melissa A Troester Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-03-01 Impact factor: 4.090
Authors: Sanah N Vohra; Katherine E Reeder-Hayes; Hazel B Nichols; Marc A Emerson; Michael I Love; Andrew F Olshan; Melissa A Troester Journal: Breast Cancer Res Treat Date: 2022-01-10 Impact factor: 4.624
Authors: Jennifer K Litton; Carla L Warneke; Karin M Hahn; Shana L Palla; Henry M Kuerer; George H Perkins; Elizabeth A Mittendorf; Chad Barnett; Ana M Gonzalez-Angulo; Gabriel N Hortobágyi; Richard L Theriault Journal: Oncologist Date: 2013-04-10
Authors: Adriana Valentini; Jan Lubinski; Tomasz Byrski; Parviz Ghadirian; Pal Moller; Henry T Lynch; Peter Ainsworth; Susan L Neuhausen; Jeffrey Weitzel; Christian F Singer; Olufunmilayo I Olopade; Howard Saal; Dominique Stoppa Lyonnet; William D Foulkes; Charmaine Kim-Sing; Siranoush Manoukian; Dana Zakalik; Susan Armel; Leigha Senter; Charis Eng; Eva Grunfeld; Anna M Chiarelli; Aletta Poll; Ping Sun; Steven A Narod Journal: Breast Cancer Res Treat Date: 2013-10-18 Impact factor: 4.872
Authors: Hatem A Azim; Fedro A Peccatori; Sylvain Brohée; Daniel Branstetter; Sherene Loi; Giuseppe Viale; Martine Piccart; William C Dougall; Giancarlo Pruneri; Christos Sotiriou Journal: Breast Cancer Res Date: 2015-02-21 Impact factor: 6.466